Transcription of US/Italian Multicenter Collaboration
1 McCullough PA, Kelly RJ, Ruocco G, Lerma E, Tumlin J, Wheelan KR, Katz N, Lepor NE, Vijay K, Carter H, Singh B, McCullough SP, Bhambi BK, Palazzuoli A, De Ferrari GM, Milligan GP, Safder T, Tecson KM, Wang DD, McKinnon JE, O'Neill WW, Zervos M, Risch HA. Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection. Am J Med. 2020 Aug 7:S0002-9343(20)30673-2. doi: Epub ahead of print. PMID: 32771461; PMCID: Multicenter CollaborationAcademic Medical CentersPublic HeathIntegrated Health SystemsCommunity PracticeBiotech IndustrySpecialtiesInternal MedicineCritical CareNephrologyCardiologyElectrophysiolog yInfectious DiseasesOphthalmologyEpidemiologyBiostat isticsDay 0 Symptom Onset 7 days 14 days 21 days 30 days Untreated Mortality RiskCoughDifficulty BreathingFeverSore ThroatMalaiseBody AchesNasal StuffinessLoss of tasteAnorexiaNauseaDiarrheaChest Heaviness/PainDyspneaDesaturationSystemi c ThromboembolismOff-Target AntiviralsCorticosteroidsAntiplatelet Drugs/AntithromboticsSARS-CoV-2 Nasal PCR+Oral PCR/Ag+ D-dimer Hs-CRP LymphocytesAmbulatory Phase Hospitalization Phase DeathMcCullough PA, Fourth-Quarter 2020 COVID-19 Drug and Diagnostic Developments A Virtual Conference Monday, November 2nd2020, 9:00am -6.
2 00pm CET McCullough PA Proc (Bayl Univ Med Cent). 2020 (in press)COVID-19-like or COVID-19-confirmed illnessSelf-quarantine at home, Contagion ControlAge 50 yr. or aSingle ComorbidityBMI > 30 kg/m2, Pulmonary Dz, DM, CVD, CKD, CancerRespiratory Symptoms Develop or Day 5 of illnessPrednisone 1 mg/kg qd x 5 days taper Colchicine mg po bidUnderlying Serious Medical Condition, VTE Risk, Suspect micro- or overt thrombosisAspirin 325 mg po qd Low-molecular weight heparin orApixaban, Rivaroxaban, Dabigatran, Edoxaban in Standard doses (5-30 days)Age 50 yr. with 1 ComorbiditiesRoom AirPulse OxDeliverHome 02If NeededRe-evaluateHospitalizeEscalate ClinicallyEmpiric MgtImmediately: Fresh air/reduce reinoculation, zinc sulfate 220 mg po qd (5-30 days)Watchful WaitingIf Symptoms WorsenComplete Self-quarantineAge < 50 yr. HealthyImmediately 2 Antiviral Agents (5-30 days)HCQ 200 mg po bid+ AZM 250 mg po bid or+Doxy 100 mg po bid Favipiravir 600 mg po bid+ AZM 250 mg po bid or+Doxy 100 mg po bid IVM 6-12 mg po qd x 1-3 days+ AZM 250 mg po bid or+Doxy 100 mg po bid Adapted from McCullough PA, Kelly RJ, Ruocco G, Lerma E, Tumlin J, Wheelan KR, Katz N, Lepor NE, Vijay K, Carter H, Singh B, McCullough SP, Bhambi BK, Palazzuoli A, De Ferrari GM, Milligan GP, Safder T, Tecson KM, Wang DD, McKinnon JE, O'Neill WW, Zervos M, Risch HA.
3 Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection. Am J Med. 2020 Aug 7:S0002-9343(20)30673-2. doi: Epub ahead of print. PMID: 32771461; PMCID: PA, Fourth-Quarter 2020 COVID-19 Drug and Diagnostic Developments A Virtual Conference Monday, November 2nd2020, 9:00am - 6:00pm CET McCullough PA Proc (Bayl Univ Med Cent). 2020 (in press)BMI=body mass index, Dz=disease, DM=diabetes mellitus, CVD=cardiovascular disease, CKD=chronic kidney disease, yr=years, HCQ=hydroxychloroquine, AZM=azithromycin, Doxy=doxycycline, IVM=Ivermectin, VTE=venous thrombo-embolic
